Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof

Details for Australian Patent Application No. 2004272272 (hide)

Owner The Medicines Company (Leipzig) GmbH

Inventors Sturzebecher, Jorg; Donnecke, Daniel; Sturzebecher, Anne; Steinmetzer, Torsten; Schweinitz, Andrea

Agent Watermark

Pub. Number AU-B-2004272272

PCT Pub. Number WO2005/026198

Priority 103 42 108.4 11.09.03 DE

Filing date 13 September 2004

Wipo publication date 24 March 2005

Acceptance publication date 10 December 2009

International Classifications

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

C07K 5/065 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/078 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/087 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/097 (2006.01) Peptides having up to four amino acids in a fully defined sequence

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/026198 Priority application(s): WO2005/026198

9 April 2009 Alteration of Name

  The name of the applicant has been altered to The Medicines Company (Leipzig) GmbH

10 December 2009 Application Accepted

  Published as AU-B-2004272272

8 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004272275-1, 3-disubstituted azetidine derivatives for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases

2004272270-Genetic products which are differentially expressed in tumours and use thereof